pre-IPO PHARMA

COMPANY OVERVIEW

Apexigen is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer.


LOCATION

  • San Carlos, CA, USA

  • THERAPEUTIC AREAS

  • Immunology
  • Oncology

  • WEBSITE

    https://www.apexigen.com/


    CAREER WEBSITE

    https://www.apexigen.com/careers/


    SOCIAL MEDIA


    INVESTORS

    bioventures-capital decheng-capital sv-tech-ventures virtus-inspire-ventures


    PRESS RELEASES


    Nov 15, 2022

    Apexigen Reports Third Quarter 2022 Financial Results and Provides Business Update


    Nov 14, 2022

    Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma


    Sep 7, 2022

    Apexigen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference


    Sep 5, 2022

    Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022


    Aug 4, 2022

    Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference


    For More Press Releases


    Google Analytics Alternative